Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Feprotein is a multi-ingredient hematinic supplement developed and marketed by Jagsonpal Pharmaceuticals. It is a combination product containing carbonyl iron, folic acid, cyanocobalamin (Vitamin B12), zinc sulfate, and protein hydrolysate. The formulation is primarily indicated for the treatment and prevention of iron deficiency anemia, particularly during pregnancy and lactation, or in cases of general nutritional deficiency. Carbonyl iron serves as a source of elemental iron with high bioavailability and a lower risk of gastrointestinal toxicity compared to traditional ferrous salts. Folic acid and cyanocobalamin are essential cofactors for erythropoiesis and DNA synthesis, while zinc sulfate and protein hydrolysate provide additional nutritional support for metabolic processes and tissue repair.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on carbonyl iron + folic acid + cyanocobalamin + zinc sulfate + protein hydrolysate.